June 12, 2020 10:55 AM EDT
News Briefing

Sanofi and Re­gen­eron out­line Dupix­ent plans; In­dus­try lob­by­ing brings £30 mil­lion for UK's Bio­med­ical Cat­a­lyst

Jason Mast

Editor

→ Sanofi and Re­gen­eron out­lined the fu­ture for their block­buster IL-4/IL-13 block­er Dupix­ent in an in­vestor call and press re­lease …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Pfiz­er hires ex-FDA deputy Pa­trizia Cavaz­zoni as chief med­ical of­fi­cer

Pfiz­er wants in on Sum­mit’s goal to beat Keytru­da via ADC com­bos

Post-Hoc: Phar­ma CEOs' al­ter­na­tive re­al­i­ty with Trump

Sanofi, Te­va bol­ster case for IBD drug with Phase 2 da­ta, de­spite po­ten­tial com­pe­ti­tion

FDA lifts hold on En­trada's Duchenne drug af­ter two years

sponsored

How AI can ad­dress on­go­ing chal­lenges in the life sci­ences in­dus­try

A service from the Financial Times